111 Inc ADR(YI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.39 | Insider Own | 1.82% | Shs Outstand | 5.2M | Perf Week | 9.06% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | -93.05% | Shs Float | 5.1M | Perf Month | -4.9% |
| Enterprise Value | 0.14B | PEG | - | EPS next Q | - | Inst Own | 2.22% | Short Float | 0.19% | Perf Quarter | -23.63% |
| Income | -0.01B | P/S | 0.01 | EPS this Y | - | Inst Trans | 27.15% | Short Ratio | 0.58 | Perf Half Y | -48.45% |
| Sales | 1.60B | P/B | - | EPS next 5Y | - | ROA | -3.8% | Short Interest | 0.01M | Perf YTD | 36.33% |
| Book/sh | -12.17 | P/C | 0.32 | EPS past 3/5Y | 47.72% 33.28% | ROE | - | 52W High | -68.76% ($11.17) | Perf Year | -41.05% |
| Cash/sh | 11.06 | P/FCF | - | Sales past 3/5Y | -4.53% 8.01% | ROIC | - | 52W Low | 40.73% ($2.48) | Perf 3Y | -87.07% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -25.89% | Gross Margin | 5.74% | Volatility(W/M) | 11.34% 8.63% | Perf 5Y | -94.44% |
| Dividend TTM | - | EV/Sales | 0.08 | Sales Y/Y TTM | -19.75% | Oper. Margin | -0.27% | ATR (14) | 0.33 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.49 | EPS Q/Q | -117.06% | Profit Margin | -0.76% | RSI (14) | 48.11 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.08 | Sales Q/Q | -29.68% | SMA20 | 0.48% ($3.47) | Beta | 0.66 | Target Price | $12.01 |
| Payout | - | Debt/Eq | - | Earnings | 2026/6/4 | SMA50 | -6% ($3.71) | Rel Volume | 0.6 | Prev Close | $3.5 |
| Employees | 1063 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -31.49% ($5.09) | Avg Volume(3M) | 0.02M | Price | $3.49 |
| IPO | 2018/9/12 | Option/Short | No/Yes | Trades | 76 | Volume | 10,017 | Change | -0.29% |
Company
YI is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
111 is a Chinese digital healthcare and pharmaceutical distribution company that operates its own B2C online pharmacy, "1 Drugstore," and a B2B pharmacy wholesale platform, "1 Drugmall." Its core strategy is to build a direct supply chain for small pharmacies and hospitals, connecting China's pharmaceutical distribution through an integrated online and offline model.
Over the past 1 year, on the lower side
69% below its 1-year high.
YI has weak earning power
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -87.1% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 2.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
FBND 28.2B
USHY 27.7B
SDY 21.4B
BINC 16.4B
HYG 14.4BIt ranks #4 in the industry
Based on market cap of $18M.
YI $18M PER -
MCK $105B PER 24.1
COR $62B PER 24.0
CAH $54B PER 32.1
FAQ
What kind of company is YI?
YI belongs to the Healthcare sector and operates in the Medical Distribution industry.
What is the market cap of YI?
The market cap of YI is approximately $18M, ranking 5,301 within its sector.
What is the 52-week high and low for YI?
YI has recorded a 52-week high of $11.17 and a low of $2.48.
